Catalyst Pharmaceuticals Files 8-K
Ticker: CPRX · Form: 8-K · Filed: 2024-08-07T00:00:00.000Z
Sentiment: neutral
Topics: sec-filing, corporate-update, financials
TL;DR
Catalyst Pharma filed an 8-K on Aug 7th. Standard update.
AI Summary
Catalyst Pharmaceuticals, Inc. filed an 8-K on August 7, 2024, reporting other events and financial statements/exhibits. The company, incorporated in Delaware, is based in Coral Gables, Florida, and operates in the pharmaceutical preparations sector.
Why It Matters
This filing indicates Catalyst Pharmaceuticals is providing updates and financial information to the SEC, which is standard for public companies but can signal upcoming events or disclosures.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate reporting and does not appear to contain any immediately concerning information.
Key Numbers
- 001-33057 — SEC File Number (Identifies the company's filing with the SEC.)
- 76-0837053 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- CATALYST PHARMACEUTICALS, INC. (company) — Registrant
- August 7, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Coral Gables, Florida (location) — Principal Executive Offices
- 355 Alhambra Circle, Suite 801 (address) — Business Address
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The filing indicates 'Other Events' as an item information, but the specific details of these events are not provided in the excerpt.
What is the significance of filing 'Financial Statements and Exhibits' on an 8-K?
This indicates the company is providing updated financial information or exhibits as required by the SEC, which could include material contracts or other important documents.
When was Catalyst Pharmaceuticals, Inc. incorporated?
Catalyst Pharmaceuticals, Inc. was incorporated in Delaware.
What is the primary business address of Catalyst Pharmaceuticals, Inc.?
The primary business address is 355 Alhambra Circle, Suite 801, Coral Gables, Florida, 33134.
What is the SIC code for Catalyst Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
From the Filing
0001193125-24-195950.txt : 20240807 0001193125-24-195950.hdr.sgml : 20240807 20240807163204 ACCESSION NUMBER: 0001193125-24-195950 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240807 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240807 DATE AS OF CHANGE: 20240807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 241184352 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d873312d8k.htm 8-K 8-K NASDAQ false 0001369568 0001369568 2024-08-07 2024-08-07     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): August 7, 2024     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   355 Alhambra Circle   Suite 801   Coral Gables , Florida   33134 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company  ☐      If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events On August 7, 2024, the Company issued a press release announcing its results of operations for the three and six months ended June 30, 2024 and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1.   Item 9.01 Financial Statements and Exhibits.     (d) Exhibits   99.1